Parameterized evaluation of macromolecules and lipids in proton MR spectroscopy of brain diseases

Short echo time (TE) proton MR spectra of the brain include signals of several metabolites as well as macromolecules. In various pathologies, such as brain tumors and multiple sclerosis (MS), the presence of mobile lipids or pathologically altered macromolecules may provide useful additional diagnostic information. A reliable quantitation of these resonances, however, is often not possible due to the lack of adequate prior knowledge. Furthermore, even if advanced fitting procedures are used, a reliable evaluation of metabolites in the presence of pathological lipids or macromolecules often fails if the latter are omitted in the spectral evaluation. In this study, a method is presented for the simultaneous evaluation of all visible components, including metabolites, lipids, and macromolecules, by the use of the fitting procedure LCModel. A standard basis set of brain metabolites was extended by inclusion of parameterized components for macromolecules and lipids that were derived from metabolite‐nulled in vivo spectra of normal brain and high‐grade gliomas, respectively. The improved spectral quantitation is demonstrated in glial brain tumors and MS lesions as well as in normal brain. It is pointed out that both macromolecules and lipids must be included to provide a proper spectral evaluation. Magn Reson Med 49:19–28, 2003. © 2003 Wiley‐Liss, Inc.

[1]  J. Frahm,et al.  Localized proton NMR spectroscopy of brain tumors using short-echo time STEAM sequences. , 1991, Journal of computer assisted tomography.

[2]  K. Behar,et al.  Short echo time proton magnetic resonance spectroscopic imaging of macromolecule and metabolite signal intensities in the human brain , 1996, Magnetic resonance in medicine.

[3]  C Gössl,et al.  Improved analysis of 1H‐MR spectra in the presence of mobile lipids , 2001, Magnetic resonance in medicine.

[4]  G. Sutherland,et al.  Mobile lipid accumulation in necrotic tissue of high grade astrocytomas. , 1996, Anticancer research.

[5]  P A Narayana,et al.  Proton MR spectroscopy of gadolinium‐enhanced multiple sclerosis plaques , 1992, Journal of magnetic resonance imaging : JMRI.

[6]  G. Sutherland,et al.  Mobile lipids and metabolic heterogeneity of brain tumours as detectable by Ex Vivo 1H MR spectroscopy , 1994, NMR in biomedicine.

[7]  S. Provencher Estimation of metabolite concentrations from localized in vivo proton NMR spectra , 1993, Magnetic resonance in medicine.

[8]  E. Gotsis,et al.  In vivo proton MR spectroscopy: the diagnostic possibilities of lipid resonances in brain tumors. , 1996, Anticancer research.

[9]  F Lazeyras,et al.  Single-voxel proton brain spectroscopy exam (PROBE/SV) in patients with primary brain tumors. , 1996, AJR. American journal of roentgenology.

[10]  U. Klose In vivo proton spectroscopy in presence of eddy currents , 1990, Magnetic resonance in medicine.

[11]  A R Tate,et al.  Towards a method for automated classification of 1H MRS spectra from brain tumours , 1998, NMR in biomedicine.

[12]  S. Holland,et al.  Proton MR spectroscopic characteristics of pediatric pilocytic astrocytomas. , 1998, AJNR. American journal of neuroradiology.

[13]  F. Lazeyras,et al.  Metabolic imaging in the diagnosis of brain tumors , 1996, Current opinion in neurology.

[14]  L Vanhamme,et al.  New approach for quantitation of short echo time in vivo 1H MR spectra of brain using AMARES , 1998, NMR in biomedicine.

[15]  L. Turnbull,et al.  Combined proton MR spectroscopy and dynamic contrast enhanced MR imaging of human intracranial tumours in vivo , 2000, NMR in biomedicine.

[16]  C Boesch,et al.  Characterization of the macromolecule baseline in localized 1H‐MR spectra of human brain , 2001, Magnetic resonance in medicine.

[17]  Ian C. P. Smith,et al.  1H MRS of high grade astrocytomas: Mobile lipid accumulation in necrotic tissue , 1994, NMR in biomedicine.

[18]  W M Bovée,et al.  Improved quantification of in vivo1H NMR spectra by optimization of signal acquisition and processing and by incorporation of prior knowledge into the spectral fitting , 1990, Magnetic resonance in medicine.

[19]  U. Klose,et al.  Reliable detection of macromolecules in single‐volume 1H NMR spectra of the human brain , 2001, Magnetic resonance in medicine.

[20]  D. Saunders,et al.  Discrimination of Metabolite from Lipid and Macromolecule Resonances in Cerebral Infarction in Humans Using Short Echo Proton Spectroscopy , 1997, Journal of magnetic resonance imaging : JMRI.

[21]  G J Barker,et al.  Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. , 1994, Brain : a journal of neurology.

[22]  R. Sauter,et al.  Intratumoral lipids in 1H MRS in vivo in brain tumors: experience of the Siemens cooperative clinical trial. , 1996, Anticancer research.

[23]  S. Shibata,et al.  Diagnostic potential of short echo time MR spectroscopy of gliomas with single-voxel and point-resolved spatially localised proton spectroscopy of brain , 2001, Neuroradiology.

[24]  I Mader,et al.  In Vivo proton MR spectroscopy of human gliomas: definition of metabolic coordinates for multi‐dimensional classification , 1995, Magnetic resonance in medicine.

[25]  U Klose,et al.  Proton MR spectroscopy with metabolite-nulling reveals elevated macromolecules in acute multiple sclerosis. , 2001, Brain : a journal of neurology.

[26]  B J Soher,et al.  Automated spectral analysis I: Formation of a priori information by spectral simulation , 1998, Magnetic resonance in medicine.

[27]  R Gruetter,et al.  Toward an in vivo neurochemical profile: quantification of 18 metabolites in short-echo-time (1)H NMR spectra of the rat brain. , 1999, Journal of magnetic resonance.

[28]  K. Behar,et al.  Analysis of macromolecule resonances in 1H NMR spectra of human brain , 1994, Magnetic resonance in medicine.

[29]  D J Drost,et al.  Factors affecting the quantification of short echo in‐vivo 1H MR spectra: prior knowledge, peak elimination, and filtering , 1999, NMR in biomedicine.